To compare the in vivo anti-tumor effect of UniCAR and conventional CAR T cells, subcutaneous HER2+ MDA-HER2.ffLUC xenografts were grown in NSG mice and treated with a single i.v. dose of 2 × 106 UniCAR or HER2-CAR T cells on day 21 post tumor cell inoculation (Figure 4A, Supplementary Figure 1). This evidence concerns the gene ERBB2 and neoplasm.